Synthetic Biologics Inc (SYN) Receives $5.50 Consensus Target Price from Analysts

Synthetic Biologics Inc (NYSEMKT:SYN) has earned an average recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $5.50.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Wednesday, August 9th. ValuEngine raised shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/18/synthetic-biologics-inc-syn-receives-5-50-consensus-target-price-from-analysts.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning increased its stake in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after acquiring an additional 70,000 shares during the last quarter. Susquehanna International Group LLP increased its stake in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after acquiring an additional 82,030 shares during the last quarter. UBS Group AG increased its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after acquiring an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after acquiring an additional 7,962 shares during the last quarter. Finally, LMR Partners LLP bought a new position in Synthetic Biologics in the second quarter valued at $194,000.

Shares of Synthetic Biologics (SYN) opened at 0.8751 on Wednesday. The firm’s market cap is $112.23 million. The firm has a 50 day moving average price of $0.86 and a 200-day moving average price of $0.64. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.63.

Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. Analysts forecast that Synthetic Biologics will post ($0.17) earnings per share for the current year.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. T

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Wednesday, August 9th. ValuEngine raised shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/18/synthetic-biologics-inc-syn-receives-5-50-consensus-target-price-from-analysts.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning increased its stake in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock valued at $100,000 after acquiring an additional 70,000 shares during the last quarter. Susquehanna International Group LLP increased its stake in Synthetic Biologics by 76.4% in the second quarter. Susquehanna International Group LLP now owns 189,342 shares of the company’s stock valued at $107,000 after acquiring an additional 82,030 shares during the last quarter. UBS Group AG increased its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after acquiring an additional 20,038 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after acquiring an additional 7,962 shares during the last quarter. Finally, LMR Partners LLP bought a new position in Synthetic Biologics in the second quarter valued at $194,000.

Shares of Synthetic Biologics (SYN) opened at 0.8751 on Wednesday. The firm’s market cap is $112.23 million. The firm has a 50 day moving average price of $0.86 and a 200-day moving average price of $0.64. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.63.

Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. Analysts forecast that Synthetic Biologics will post ($0.17) earnings per share for the current year.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply